canyon landscape

The purpose of this study is to evaluate the efficacy, safety, and tolerability of HYQVIA/HyQvia as a maintenance therapy to prevent relapse and for the treatment of CIDP. Subjects must be on a stable dosing regimen of IVIG therapy for at least 12 weeks prior to enrollment.

For up to the first 8 weeks, subjects will continue to receive their own IVIG treatment at the same dose and frequency as prescribed prior to entry into the study. Then, subjects will be randomized to receive HyQvia administered through a subcutaneous infusion (i.e. a small needle inserted under the skin) every 2, 3, or 4 weeks for a total of 10 to 15 weeks. Overall, participants may be in the research study for about 28 weeks.

Principal Investigator: Suraj Muley, MD

Status
Open and enrolling subjects.
Location
Phoenix, Arizona
Primary Sponsor
Baxalta US Inc. and Baxalta Innovations GmbH